Inclusion Criteria:
1. Participant must have Newly diagnosed multiple myeloma. Newly diagnosed subjects must
have symptomatic disease following the IMWG updated criteria (Rajkumar Lancet 2014,
Appendix 6).
2. Participant must have a measurable secretory disease defined as either serum
monoclonal protein of ≥ 0,5 g/dl or urine monoclonal (light chain) protein ≥
200mg/24h.For patients whose disease is only measurable by serum FLC, the involved FLC
should be ≥ 10mg/L (100 mg/dl), with an abnormal serum FLC ratio.
3. Newly diagnosed participants must be eligible for stem cell transplant at investigator
criteria.
4. Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status
of ≤ 2. 5. Participant must be ≥ 18 years of age. 6. Participant must have adequate organ function, defined as follows:
System Laboratory Values Hematologic Absolute neutrophil count (ANC) ≥1.5 X 109/L
Hemoglobin ≥8.0 g/dL Platelets ≥75 x 109/L for subjects in whom <50% of bone marrow
nucleated cells are plasma cells; otherwise platelet count >50 × 109/L Calcium
corrected serum calcium <14 mg/dL (<3.5 mmol/L); or free ionized calcium <6.5 mg/dL
(<1.6 mmol/L); Hepatic Total bilirubin ≤1.5X ULN (Isolated bilirubin ≥1.5xULN is
acceptable if bilirubin is fractionated and direct bilirubin <35%) ALT ≤2.5 X ULN AST
≤2.5 X ULN Renal eGFRa ≥30 mL/min/ 1.73 m2 Spot urine (albumin/creatinine ratios (spot
urine) <500 mg/g (56 mg/mmol)
7. Female participants: contraceptive use should be consistent with local regulations
regarding the methods of contraception for those participating in clinical studies.
A female participant is eligible to participate if she is not pregnant or
breastfeeding, and at least one of the following conditions applies:
- - Is not a woman of childbearing potential (WOCBP) OR.
- - Is a WOCBP and using a contraceptive method that is highly effective (with a
failure rate of <1% per year), preferably with low user dependency, during the
intervention period and for at least 4 months after the last dose of study
intervention and agrees not to donate eggs (ova, oocytes) for the purpose of
reproduction during this period.
The investigator should evaluate the
effectiveness of the contraceptive method in relationship to the first dose of
study intervention.
A WOCBP must have a negative highly sensitive serum pregnancy test (as required by
local regulations) within 72 hours before the first dose of study intervention and
agree to use a highly effective method of contraception during the study and for 4
months after the last dose of belantamab mafodotin. Additional requirements for
pregnancy testing during and after study intervention The investigator is responsible
for review of medical history, menstrual history, and recent sexual activity to
decrease the risk for inclusion of a woman with a nearly undetected pregnancy.
Nonchildbearing potential is defined as follows (by other than medical reasons):
- - ≥45 years of age and has not had menses for >1 year.
- - Patients who have been amenorrhoeic for <2 years without history of a
hysterectomy and oophorectomy must have a follicle stimulating hormone value in
the postmenopausal range upon screening evaluation Post-hysterectomy,
post-bilateral oophorectomy, or post-tubal ligation.
Documented hysterectomy or
oophorectomy must be confirmed with medical records of the actual procedure or
confirmed by an ultrasound. Tubal ligation must be confirmed with medical records
of the actual procedure.
8. Male participants: contraceptive use should be consistent with local regulations
regarding the methods of contraception for those participating in clinical studies.
Male participants are eligible to participate if they agree to the following during
the intervention period and for at least 6 months:
- - Refrain from donating sperm.
PLUS either:
- - Be abstinent from heterosexual intercourse as their preferred and usual lifestyle
(abstinent on a long term and persistent basis) and agree to remain abstinent.
OR.
- - Must agree to use contraception/barrier as detailed below:
Agree to use a male condom and female partner to use an additional highly effective
contraceptive method with a failure rate of <1% per year as when having sexual
intercourse with a woman of childbearing potential (including pregnant females).
All
prior treatment-related toxicities (defined by National Cancer Institute- Common
Toxicity Criteria for Adverse Events (NCI-CTCAE), version 4.0 (must be ≤ Grade 1 at
the time of enrolment except for alopecia).
9. Participant must be able to understand the study procedures and agree to participate
in the study by providing written informed consent.
Exclusion Criteria:
Patients that present any of the following exclusion criteria cannot be included in the
trial:
1. Participant has a diagnosis of primary amyloidosis, monoclonal gammopathy of
undetermined significance (MGUS), smoldering multiple myeloma (SMM), plasma cell
leukemia or active POEMS syndrome at the time of screening.
2. Participant has malignancies other than disease under study, except for any other
malignancy from which the participant has been disease-free for more than 2 years and,
in the opinion of the principal investigators, will not affect the evaluation of the
effects of this clinical trial treatment on the currently targeted malignancy.
Participants with curatively treated non-melanoma skin cancer may be enrolled.
3. Participant has meningeal involvement of multiple myeloma.
4. Pregnant or breastfeeding females.
5. Participant is simultaneously enrolled in other interventional clinical trial.
6. Participant must has used an investigational drug within 14 days or five half-lives,
whichever is shorter, preceding the first dose of study drug.
7. Participant has used of any anti-myeloma drug therapy, except for steroid pulses in
case of emergency (40 mg of dexamethasone for 4 days), the administration of
bisphosphonates or antialgic radiotherapy or due to the presence of plasmacytomas
requiring some emergency.
8. Participant who have received prior treatment with a monoclonal antibody within 30
days of receiving the first dose of study drugs.
9. Participant has a known immediate or delayed hypersensitivity reaction or idiosyncrasy
to drugs chemically related to: belantamab mafodotin, lenalidomide, boronic acid
(bortezomib), dexamethasone or any of the components of the study treatment.
10. Participant who have had major surgery ≤ 4 weeks prior to initiating protocol therapy.
11. Participant who have current corneal epithelial disease except mild punctate
keratopathy. 12. Participant has peripheral neuropathy or neuropathic pain grade ≥2, as defined by the
National Cancer Institute Terminology Criteria for Adverse Events (NCI CTCAE) Version
4.0 (APPENDIX 4).
13. Participant is unable or unwilling to undergone antithrombotic prophylactic treatment. 14. Participant evidence of cardiovascular risk including any of the following:
- - Evidence of current clinically significant uncontrolled arrhythmias, including
clinically significant ECG abnormalities such as 2nd degree (Type II) or 3rd
degree atrioventricular (AV) block.
- - History of myocardial infarction, acute coronary syndromes (including unstable
angina), coronary angioplasty, or stenting or bypass grafting within three months
of Screening.
- - Class III or IV heart failure as defined by the New York Heart Association
functional classification system [NYHA, 1994]
- Uncontrolled hypertension.
15. Incidence of gastrointestinal disease that may significantly alter the absorption of
Lenalidomide.
16. Participant must not have current unstable liver or biliary disease defined by the
presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or
gastric varices, persistent jaundice, or cirrhosis. Note: Stable chronic liver disease
(including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement
of malignancy is acceptable if otherwise meets entry criteria. 17. Presence of active renal condition (infection, requirement for dialysis or any other
condition that could affect patient's safety). Participants with isolated proteinuria
resulting from MM are eligible, provided they fulfil inclusion criteria. 18. Participant who use contact lenses while participating in this study, except if
contact lenses are removed during participation in the study. 19. Participant who have had plasmapheresis within 7 days prior to first dose of study
treatment.
20. Evidence of active mucosal or internal bleeding.
21. Any serious medical condition or psychiatric illness that would interfere in
understanding of the informed consent form.
22. Uncontrolled endocrine diseases (i.e. diabetes mellitus, hypothyroidism or
hyperthyroidism) (i.e. requiring relevant changes in medication within the last month,
or hospital admission within the last 3 months).
23. Patients with acute diffuse infiltrative pulmonary disease and/or pericardial disease.
24. Patients with severe chronic obstructive pulmonary disease (COPD) or asthma with
forced expiratory volume in the first minute (FEV1) less than 50%.
25. The subject is seropositive for human immunodeficiency virus (HIV) or presence of
active hepatitis B infection (documented by a positive test for hepatitis B surface
antigen [HBsAg], or hepatitis C (documented by a positive test for the surface antigen
of hepatitis C [HCsAg] or positive quantification of HCV RNA Note: Participants with
positive Hepatitis C antibody due to prior resolved disease can be enrolled, only if a
confirmatory negative Hepatitis C RNA test is obtained.
Note: Hepatitis RNA testing is optional and participants with negative Hepatitis C antibody
test are not required to also undergo Hepatitis C RNA testing.
